Serum levels of soluble IL-2 receptor α, IL-6 and IL-1 receptor antagonist in schizophrenia before and during neuroleptic administration

Serum levels of soluble IL-2 receptor α, IL-6 and IL-1 receptor antagonist in schizophrenia before and during neuroleptic administration
复制标题

DOI:
10.1016/s0920-9964(98)00140-6
复制
发表时间:
1999-05-04
影响因子:
4.5
通讯作者:
Akiyama, K
Akiyama, K
中科院分区:
医学2区
文献类型:
--
作者:
Akiyama, K

文献摘要

被引文献

相似文献

在为期8周的精神分裂症治疗方案中,在服用抗精神病药之前和期间测定血清白细胞介素-2可溶性受体α(IL-2sR α)、白细胞介素-6(IL-6)和白细胞介素-1受体拮抗剂(IL-1 ra)水平。与对照组相比,精神分裂症患者在第0、1、4和8周显示出显著较高的血清IL-2sR α、IL-6和IL-1 ra水平,并且在第1周的血清IL-2sR α水平与发病年龄之间存在显著负相关。未接受过抗精神病药物治疗的精神分裂症患者治疗前血清IL-2sR α、IL-6和IL-1 ra水平显著高于对照组。第0周和第1周的IL-2sR α水平与第4周的精神病理学评分(使用阳性和阴性症状量表进行评估)之间存在显著正相关。第0、1、4周的IL-6水平与病程呈显著正相关。第1周IL-1 ra水平与第1周阳性症状显著正相关。本研究支持的建议,在免疫系统的变化参与精神分裂症的病理生理。(C)1999年由Elsevier Science B. V.出版,版权所有。
Serum levels of interleukin-2 soluble receptor alpha (IL-2sR alpha), interleukin-6 (IL-6) and interleukin-l receptor antagonist (IL-1ra) were determined both before and during neuroleptic administration in an 8-week treatment protocol for schizophrenia. In comparison with a control group, schizophrenia patients showed significantly higher serum levels of IL-2sR alpha, IL-6 and IL-1ra at weeks 0, 1, 4 and 8, and there was a significant negative correlation between the serum level of IL-2sR alpha at week 1 and the age at illness onset. Those of the schizophrenia patients who were neuroleptic-naive had significantly higher pretreatment serum levels of IL-2sR alpha, IL-6 and IL-1ra than the controls. There were significant positive correlations between the IL-2sR alpha levels at weeks 0 and 1, and the psychopathology scores, evaluated using the positive and negative syndrome scale at week 4. IL-6 levels at weeks 0, 1 and 4 were significantly and positively correlated with the duration of illness. The IL-1ra level at week 1 was significantly and positively correlated with positive symptoms at week 1. The present study supports the suggestion that changes in the immune system are involved in the pathophysiology of schizophrenia. (C) 1999 Published by Elsevier Science B.V. All rights reserved.